Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for treating coronary heart disease

A composition and technology for coronary heart disease, applied in the fields of medicine and pharmacy, can solve the problems of large dosage, unclear mechanism of action, unclear metabolism in the body, etc., and achieve the effect of simple composition and treatment of coronary heart disease

Inactive Publication Date: 2020-05-19
XIAN CHIHO PHARMA
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, the Gelanxinning soft capsules in the prior art have the problems of large dosage, unclear mechanism of action, and unclear metabolism in the body.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating coronary heart disease
  • Composition for treating coronary heart disease
  • Composition for treating coronary heart disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0061] Example 1 a composition

[0062] The composition described in this embodiment consists of the following components in parts by weight (1 part by weight=100g):

[0063] 5 parts by weight of puerarin D, 15 parts by weight of 3'-methoxydaidzin, 5 parts by weight of formononetin, 30 parts by weight of 3'-methoxypuerarin, 25 parts by weight of puerarin, 3'-hydroxypuerarin 30 parts by weight of ginseng, 1.0 parts by weight of maslinic acid, 1.0 parts by weight of hyperoside, 2.0 parts by weight of gypenoside A, 1.5 parts by weight of gypenoside LXXV and 2.0 parts by weight of gypenoside XLIX.

[0064] The above components are uniformly mixed in parts by weight to obtain the target composition.

Embodiment 2

[0065] Example 2 a composition

[0066] The composition described in this embodiment consists of the following components in parts by weight (1 part by weight=100g):

[0067] 2 parts by weight of puerarin D, 7 parts by weight of 3'-methoxydaidzein, 2 parts by weight of formononetin, 15 parts by weight of 3'-methoxypuerarin, 42 parts by weight of puerarin, 3'-hydroxypuerarin 15 parts by weight of quinine, 0.8 parts by weight of maslinic acid, 0.8 parts by weight of hyperoside, 1.8 parts by weight of gypenoside A, 1.2 parts by weight of gypenoside LXXV and 1.8 parts by weight of gypenoside XLIX.

[0068] The above components are uniformly mixed in parts by weight to obtain the target composition.

Embodiment 3

[0069] Example 3 a composition

[0070] The composition described in this embodiment consists of the following components in parts by weight (1 part by weight=100g):

[0071] 3.5 parts by weight of puerarin D, 8.5 parts by weight of 3'-methoxydaidzin, 3.5 parts by weight of formononetin, 18 parts by weight of 3'-methoxypuerarin, 38 parts by weight of puerarin, 3'-hydroxypuerarin 22 parts by weight of ginseng, 0.5 parts by weight of maslinic acid, 0.5 parts by weight of hyperoside, 1.4 parts by weight of gypenoside A, 1.1 parts by weight of gypenoside LXXV and 1.7 parts by weight of gypenoside XLIX.

[0072] The above components are uniformly mixed in parts by weight to obtain the target composition.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a composition for coronary heart disease and a medical application of the composition. The composition includes the following components in parts by weight: 1-5 parts by weightof puerarinoid D, 5-15 parts by weight of 3'-methoxydaidzin, 1-5 parts by weight of ononin, 10-30 parts by weight of 3'--methyoxy-puerarin, 25-45 parts by weight of puerarin, 10-30 parts by weight of3'-hydroxypuerarin, 0.2-1.0 part by weight of maslinic acid, 0.2-1.0 part by weight of hyperoside, 1.0-2.0 parts by weight of gypenoside A, 0.5-1.5 parts by weight of gypenoside LXXV and 1.0-2.0 partsby weight of gypenoside XLIX. The composition provided by the invention can significantly improve the pathological state of the coronary heart disease by normalizing disordered sphingolipid metabolism and glycerophospholipid metabolism of the coronary heart disease.

Description

technical field [0001] The invention belongs to the fields of medicine and pharmacy, and in particular relates to a pharmaceutical composition for treating coronary heart disease. Background technique [0002] Coronary heart disease, referred to as coronary heart disease, is a myocardial ischemia hypoxia (angina pectoris) or myocardial necrosis (myocardial infarction) caused by coronary artery organic (atherosclerosis or dynamic vasospasm) stenosis or obstruction. heart disease, also known as ischemic heart disease. The most common cause of coronary heart disease is atherosclerosis, accounting for about 90%. Other rare causes include connective tissue disease, rheumatic heart disease, Kawasaki disease, syphilitic cardiovascular disease, coronary embolism, Takayasu arteritis, dissecting aneurysm, coronary malformation, trauma, etc. More than 95% of myocardial infarction develops from coronary heart disease, and the mortality rate of acute myocardial infarction is very high,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K31/704A61K31/352A61K31/56A61P9/10A61K36/424
CPCA61K31/7048A61K31/704A61K31/352A61K31/56A61P9/10A61K36/424A61K2300/00
Inventor 胡小虎张琼吕慧锋谭祥和胡小艳
Owner XIAN CHIHO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com